1. Home
  2. DCTH vs SPXX Comparison

DCTH vs SPXX Comparison

Compare DCTH & SPXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DCTH
  • SPXX
  • Stock Information
  • Founded
  • DCTH 1988
  • SPXX 2004
  • Country
  • DCTH United States
  • SPXX United States
  • Employees
  • DCTH N/A
  • SPXX N/A
  • Industry
  • DCTH Medical/Dental Instruments
  • SPXX Trusts Except Educational Religious and Charitable
  • Sector
  • DCTH Health Care
  • SPXX Finance
  • Exchange
  • DCTH Nasdaq
  • SPXX Nasdaq
  • Market Cap
  • DCTH 379.5M
  • SPXX 302.8M
  • IPO Year
  • DCTH N/A
  • SPXX N/A
  • Fundamental
  • Price
  • DCTH $12.11
  • SPXX $17.37
  • Analyst Decision
  • DCTH Strong Buy
  • SPXX
  • Analyst Count
  • DCTH 4
  • SPXX 0
  • Target Price
  • DCTH $21.50
  • SPXX N/A
  • AVG Volume (30 Days)
  • DCTH 389.9K
  • SPXX 51.3K
  • Earning Date
  • DCTH 11-08-2024
  • SPXX 01-01-0001
  • Dividend Yield
  • DCTH N/A
  • SPXX 7.55%
  • EPS Growth
  • DCTH N/A
  • SPXX N/A
  • EPS
  • DCTH N/A
  • SPXX N/A
  • Revenue
  • DCTH $22,644,000.00
  • SPXX N/A
  • Revenue This Year
  • DCTH $1,605.13
  • SPXX N/A
  • Revenue Next Year
  • DCTH $111.67
  • SPXX N/A
  • P/E Ratio
  • DCTH N/A
  • SPXX N/A
  • Revenue Growth
  • DCTH 945.91
  • SPXX N/A
  • 52 Week Low
  • DCTH $3.10
  • SPXX $13.57
  • 52 Week High
  • DCTH $12.88
  • SPXX $16.05
  • Technical
  • Relative Strength Index (RSI)
  • DCTH 60.66
  • SPXX 45.96
  • Support Level
  • DCTH $11.48
  • SPXX $17.66
  • Resistance Level
  • DCTH $12.38
  • SPXX $18.00
  • Average True Range (ATR)
  • DCTH 0.70
  • SPXX 0.16
  • MACD
  • DCTH 0.06
  • SPXX -0.03
  • Stochastic Oscillator
  • DCTH 77.56
  • SPXX 7.35

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

About SPXX Nuveen S&P 500 Dynamic Overwrite Fund

Nuveen S&P 500 Dynamic Overwrite Fund is a diversified closed-end management investment company. Its investment objective is to seek attractive total returns with less volatility than the S&P 500 Index by investing in a U.S. equity portfolio that seeks to substantially replicate the price movements of the S&P 500 Index, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio (with a 55% long-term target) in an effort to enhance the Fund's risk-adjusted returns.

Share on Social Networks: